Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.

Cancer research - 1 Jun 2009

Komarova Natalia L, Wodarz Dominik

Abstract excerpt

During therapy for chronic myeloid leukemia (CML), decline of the number of BCR-ABL transcripts has been shown to follow a biphasic pattern, with a fast phase followed by a slower phase. Hence, sustained remission requires a long phase of therapy. Data indicate that a combination of different available targeted drugs might prevent treatment failure due to drug resistance, especially at advanced stages of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Genes, abl
Share to Kinetics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Models, Biological

Share to Substrate Specificity

Share to Treatment Outcome

Share to Tumor Burden

Source

Identifiers

PMID: 19458080
DOI: 10.1158/0008-5472.CAN-08-1959

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.PMID 19458080Read ↗

Drug resistance in cancer: Principles of emergence and preventionSemantic proximity Read ↗

Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models.Semantic proximity Read ↗

Data and implication based comparison of two chronic myeloid leukemia models.Semantic proximity Read ↗

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.Semantic proximity Read ↗

Cancer therapy: Attempt cure or manage drug resistance?Semantic proximity Read ↗

To cure or not to cure: consequences of immunological interactions in CML treatmentSemantic proximity Read ↗

Effect of cellular quiescence on the success of targeted CML therapy.Semantic proximity Read ↗

Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?Semantic proximity Read ↗

Predicting treatment-free remission outcomes in Chronic Myeloid Leukemia patients using an integrated model of tumor-immune dynamicsSemantic proximity Read ↗

Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemiaSemantic proximity Read ↗

Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia.Semantic proximity Read ↗

TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.